Minute Insight: The Illumina-Grail Dream Is Over... In Europe

More than a year after it first rejected the merger, the European Commission has flexed its regulatory might and has ordered the two companies to separate.

Minute Insight
• Source: Citeline/Alamy

The European Commission has mandated that sequencing technology developer Illumina must sell liquid- biopsy manufacturer Grail, after what feels like a near eternity of forward and backward discussions.

More from Diagnostics

More from Device Area